Retatrutide

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly that simultaneously activates three hormone receptors: GLP-1, GIP, and glucagon. This “triple agonist” approach represents the next generation beyond dual agonists like tirzepatide (Zepbound/Mounjaro) and has produced the largest weight loss numbers ever recorded in clinical trials of any anti-obesity medication.

Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), retatrutide adds glucagon receptor activation to the mix. The glucagon component is the key differentiator — it increases energy expenditure, enhances hepatic fat oxidation, and may directly reduce liver fat content, effects not achieved through GLP-1 or GIP agonism alone.

Retatrutide is not FDA-approved and remains in Phase 3 clinical trials (the TRIUMPH program). It is not the same molecule as grey-market “GLP-1 peptides” — it is a proprietary investigational drug with no legal compounding pathway.

How It Works

Retatrutide engages three distinct receptor pathways:

GLP-1 receptor agonism: Reduces appetite, slows gastric emptying, enhances insulin secretion. This is the same pathway as semaglutide and the primary driver of weight loss in existing approved therapies.

GIP receptor agonism: Enhances beta-cell insulin secretion, may improve lipid metabolism, and appears to augment GLP-1-mediated weight loss through mechanisms not fully understood. Retatrutide is notably more potent at human GIP receptors than at GLP-1 or glucagon receptors.

Glucagon receptor agonism: Increases hepatic glucose output (requiring the GLP-1 component to offset hyperglycemia), enhances energy expenditure, stimulates fat oxidation in the liver, and reduces hepatic lipid accumulation. The glucagon component may also reduce LDL cholesterol through PCSK9 degradation. This third mechanism is what potentially separates retatrutide from dual agonists in terms of both weight loss efficacy and liver fat reduction.

The three pathways are designed to be complementary — GLP-1 and GIP suppress appetite and improve glucose homeostasis, while glucagon ramps up energy expenditure and hepatic fat clearance.

What the Research Actually Shows

The Clinical Data

Retatrutide has more clinical data than most peptides in our database — Phase 2 trials published in NEJM and Lancet, plus the first Phase 3 results in December 2025.

Jastreboff AM et al. (NEJM, 2023;389:514–526): Phase 2 trial in 338 adults with obesity (no diabetes). At 48 weeks, the 12 mg dose produced 24.2% mean weight loss vs 2.1% placebo. At this dose, 100% of participants lost ≥5%, 93% lost ≥10%, and 83% lost ≥15% of body weight. This was the largest weight loss reported for any anti-obesity drug at the time of publication. GI side effects (nausea, diarrhea, vomiting) were the most common adverse events.

Rosenstock J et al. (Lancet, 2023;402:529–544): Phase 2 trial in 281 adults with T2D. At 36 weeks, the 12 mg dose produced 16.9% weight loss and 2.2% HbA1c reduction. 77–82% of participants achieved euglycemia (HbA1c ≤6.5%). Retatrutide was superior to dulaglutide 1.5 mg on both weight and glycemic endpoints.

Sanyal AJ et al. (Nat Med, 2024;30:2037–2048): Substudy in 98 participants with metabolic dysfunction-associated steatotic liver disease (MASLD) and ≥10% liver fat. At 24 weeks, liver fat reduction was 82.4% with 12 mg vs +0.3% placebo. Over 90% of participants on the highest dose achieved normalization of liver fat. This is a potentially transformative finding — no approved treatment for MASLD/MASH exists.

TRIUMPH-4 Phase 3 results (Eli Lilly press release, December 2025): In adults with obesity and knee osteoarthritis, the 12 mg dose produced 28.7% mean weight loss (~71.2 lbs average) and 75.8% reduction in WOMAC pain score at 68 weeks. Systolic blood pressure decreased by 14.0 mmHg. This is the first successful Phase 3 readout for retatrutide.

What’s Missing

• No FDA approval — Phase 3 trials (TRIUMPH program) are ongoing with seven additional readouts expected in 2026
• No long-term safety data beyond 68 weeks
• Discontinuation rates of 12–18% due to adverse events at the highest doses — higher than tirzepatide
• No cardiovascular outcomes trial completed (one is ongoing)
• Unknown effects on lean mass — the degree of muscle loss vs fat loss at 24–29% total weight reduction is a significant concern

Safety Profile

The safety profile in trials has been consistent with other incretin-based therapies, with dose-dependent GI side effects:

Common: Nausea (most frequent), diarrhea, vomiting, constipation, decreased appetite. These were mostly mild-to-moderate and occurred primarily during dose escalation. A slower escalation (starting at 2 mg rather than 4 mg) reduced GI adverse event frequency.

Discontinuation: At the highest doses (8–12 mg), 6–18% of participants discontinued due to adverse events vs 0–4% with placebo. The TRIUMPH-4 data showed 12.2% (9 mg) and 18.2% (12 mg) discontinuation rates — higher than seen with tirzepatide or semaglutide in comparable trials.

Cardiovascular markers: Retatrutide improved multiple cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure. LDL cholesterol was reduced by approximately 20%, potentially through glucagon-mediated PCSK9 degradation.

Potential concerns not yet resolved: The degree of lean mass loss at 25–29% total weight reduction, long-term effects of sustained triple hormone receptor activation, and the full safety profile in populations with renal or hepatic impairment.

Legal and Regulatory Status

FDA: Retatrutide is an investigational new drug under active clinical development by Eli Lilly. It has no approved indication. FDA approval is projected for 2027 based on the TRIUMPH Phase 3 program timeline. Seven more Phase 3 readouts are expected in 2026.

Compounding: There is no legal compounding pathway for retatrutide. It is a proprietary Eli Lilly molecule that has never been FDA-approved, has no USP monograph, and does not appear on any compounding bulks list.

Grey market: Retatrutide is already appearing on grey-market research chemical sites despite having no legal basis. Grey-market retatrutide carries all the standard quality risks plus additional concerns: as a triple agonist with potent glucagon activity, misdosing could cause significant metabolic disruption.

WADA: Not explicitly named on the 2026 Prohibited List but would likely be classified under S0 (Non-Approved Substances) as an unapproved investigational drug.

Common Vendor Claims vs. Reality

What vendors say	What the evidence shows
”Strongest weight loss peptide available”	Phase 2/3 data shows the largest weight reductions of any drug in trials — but it is not available legally
”Better than semaglutide/tirzepatide”	No head-to-head comparison trials exist
”Fixes fatty liver”	Phase 2 MASLD data is impressive (82% liver fat reduction) but this is a single substudy, not a confirmed indication
”Available for research use”	Standard grey-market legal fiction — the FDA’s Intended Use Doctrine applies
”Same as what Lilly is testing”	Grey-market products are unverified; no way to confirm identity or concentration
”FDA approval expected soon”	Earliest possible approval is 2027; full Phase 3 program still underway

The Bottom Line

Retatrutide’s clinical data is genuinely impressive. It has produced the largest weight reductions ever recorded in controlled trials, with remarkable liver fat reduction and significant improvements in osteoarthritis pain. The science is real and the data is strong.

But retatrutide is not available. It is an investigational drug undergoing Phase 3 trials. There is no legal pathway to obtain it — not through compounding pharmacies, not through research chemical vendors. Anyone selling “retatrutide” is selling an unverified product for an unapproved drug. If you want what retatrutide offers, the approved drugs in the same class — semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) — are available through legitimate medical channels and have completed the safety evaluation process that retatrutide is still undergoing.

---

This profile will be updated as new research becomes available. Last reviewed: March 2, 2026.